Proposed amendments to New Drugs and Clinical Trial Rules will scrap test licences, cut application processing time. Move part of govt effort to establish India as hub for pharma R&D.
Analysts from AllianceBernstein point to four areas where India lags behind its Asian peers and underline that nation finds no mention in global healthcare innovation index.
Production of PenG, used to treat tetanus, strep infections, syphilis, pneumonia & more, was stopped in India in 1990s after cheaper alternatives began surfacing in global market.
Under revised good manufacturing practices (GMP) norms, pharma companies will be required to assume onus for quality of drugs to ensure they do not place patients at risk.
India is the world's third largest maker of drugs by volume, and US sales, which account for 30% of total pharma exports, have risen by 6.2% last year.
With bad loans shrinking & capital buffers stronger, urban co-op banks’ new umbrella body NUCFDC is now prioritising rollout of digital transformation.
If deal goes through, Greece will be 2nd foreign country to procure vehicle. Morocco was first; TATA Group has set up manufacturing unit there with minimum 30 percent indigenous content.
Many of you might think I got something so wrong in National Interest pieces written this year. I might disagree! But some deserve a Mea Culpa. I’d deal with the most recent this week.
COMMENTS